These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 20853062)
1. Triple-negative breast cancers: unique clinical presentations and outcomes. Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062 [TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy]. Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696 [TBL] [Abstract][Full Text] [Related]
3. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer]. Wang YJ; Wang N; Wang B; Qin WX; Xue CY Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082 [TBL] [Abstract][Full Text] [Related]
4. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey. Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D J BUON; 2013; 18(3):619-22. PubMed ID: 24065473 [TBL] [Abstract][Full Text] [Related]
5. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948 [TBL] [Abstract][Full Text] [Related]
6. Hormone receptor-negative breast cancer: undertreatment of patients over 80. Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924 [TBL] [Abstract][Full Text] [Related]
7. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas. Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150 [TBL] [Abstract][Full Text] [Related]
8. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer. Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698 [TBL] [Abstract][Full Text] [Related]
9. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases. Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I J BUON; 2012; 17(2):277-83. PubMed ID: 22740206 [TBL] [Abstract][Full Text] [Related]
10. A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study. Chaiwun B; Nakrungsee S; Sukhamwang N; Srisukho S Breast Cancer; 2010; 17(1):35-41. PubMed ID: 19789946 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512 [TBL] [Abstract][Full Text] [Related]
12. Is triple negative a prognostic factor in breast cancer? Nishimura R; Arima N Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692 [TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer. Cefaro GA; Genovesi D; Trignani M; DI Nicola M Anticancer Res; 2014 Mar; 34(3):1207-12. PubMed ID: 24596361 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression. Demir H; Turna H; Can G; Ilvan S J BUON; 2010; 15(4):774-82. PubMed ID: 21229645 [TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival. Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N Oncology; 2013; 84(3):135-40. PubMed ID: 23235554 [TBL] [Abstract][Full Text] [Related]
16. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572 [TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer]. Zhang P; Xu BH; Ma F; Li Q Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):128-31. PubMed ID: 20403244 [TBL] [Abstract][Full Text] [Related]
18. Is there a low-grade precursor pathway in breast cancer? King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747 [TBL] [Abstract][Full Text] [Related]
19. An unusual triple-negative breast carcinoma. Shousha S; Peston D; Gojis O; Palmieri C Histopathology; 2009 Sep; 55(3):364-6. PubMed ID: 19723156 [No Abstract] [Full Text] [Related]
20. Clinical and biological characteristics of breast cancer. Kocic B; Filipovic S; Petrovic B; Mijalkovic D; Rancic N; Poultsidi A J BUON; 2010; 15(4):660-7. PubMed ID: 21229626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]